Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

Author(s):
Judson, I.; Verweij, J.; Gelderblom, H.; Hartmann, J.T.; Schoffski, P.; Blay, J.Y.; Kerst, J.M.; Sufliarsky, J.; Whelan, J.; Hohenberger, P.; Krarup-Hansen, A.; Alcindor, T.; Marreaud, S.; Litiere, S.; Hermans, C.; Fisher, C.; Hogendoorn, P.C.W. (0000-0002-1513-8104); Tos, A.P. dei; Graaf, W.T.A. van der; European Org; Treatment Canc Soft Tissue Bone Sa
Published
2014
Publication type
Article / Letter to editor
Date issued
2014-04-30
Language
English
Is part of
The Lancet Oncology (2014), Vol. 15, no. 4, p. 415-423
hdl
1887/104639
doi
10.1016/S1470-2045(14)70063-4